ReviewCellular oncology (Dordrecht, Netherlands)2025
Trends in immunotherapy for oral squamous cell carcinoma.
Review in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inflammation-driven carcinogenesis in oral cancer: A systematic review of cellular mechanisms and clinical perspectives.The Indian journal of medical research · 2026Pooled it
- METTL14-mediated m6A modification of CXCL9 mRNA regulates macrophage CS polarization to suppress OSCC growth and stemness.Functional & integrative genomics · 2026Article
- Suspected Donor-Site Implantation of Floor of Mouth Squamous Cell Carcinoma After Free Flap Reconstruction: A Case Report.The American journal of case reports · 2026Article
- Review
- A weakly supervised deep learning model for OSCC diagnosis and lesion highlighting in histopathology images.Translational cancer research · 2026Article
- Observational
- Immunohistochemical Study of the Tumor Immune Microenvironment in p16-Positive and p16-Negative Oral Squamous Cell Carcinoma and Its Prognostic Implications.Diagnostics (Basel, Switzerland) · 2026Article
- CXCL10 as a migration-associated biomarker in oral squamous cell carcinoma.BMC oral health · 2026Article
- Transmembrane protein 9 as a novel biomarker promotes oral squamous cell carcinoma growth via IL1RN and serves as an immune therapeutic target.Translational cancer research · 2026Article
- Article
- Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms.Frontiers in cell and developmental biology · 2026Review
- Emotional distress is associated with neuroendocrine-immune remodeling and less favorable neoadjuvant immunotherapy outcomes in oral squamous cell carcinoma.Frontiers in immunology · 2026Article
- NLRX1 contributes to immunotherapeutic resistance of head and neck squamous cell carcinoma by suppressing type I interferon pathway.Frontiers in immunology · 2026Article
- Hypoxic Reprogramming of ACOX1-Driven HSP90AB1 Crotonylation Stabilizes Thioredoxin to Orchestrate Redox Homeostasis in Oral Squamous Cell Carcinoma.Research (Washington, D.C.) · 2026Article
- De-escalating radiotherapy in pathologic complete response oral cancer after neoadjuvant immunochemotherapy: equal survival, better life, and a biomarker guide.Frontiers in oncology · 2026Article
- Sestrin2 Knockdown Impairs Proliferation, Migration, Invasion, and Apoptosis in OSCC Cells via PI3K/AKT/mTOR and MAPK Pathways.Current issues in molecular biology · 2025Article
- Article
- Liriopesides B inhibits proliferation and metastasis and induces apoptosis of oral squamous cell carcinoma via the PI3K/Akt/mTOR signaling pathway.Translational cancer research · 2025Article
- Article
- Prognosis of second primary oral squamous cell carcinoma after hematologic malignancy: a retrospective cohort analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor of the head and neck, characterized by an immunosuppressive tumor microenvironment. The traditional treatment approach for OSCC typically involves a combination of surgical resection, radiotherapy, and chemotherapy. Over the last few decades, the 5-year overall survival rate for OSCC has remained relatively stagnant at approximately 50-60%. Recently, the rapid progress in immunotherapy has revolutionized OSCC treatment, particularly through the use of immune checkpoint blockade therapies. Nivolumab and pembrolizumab have been approved by the US Food and Drug Administration (FDA) for the immunotherapy of head and neck squamous cell carcinoma (HNSCC). Additionally, other modalities such as costimulatory agonists, adoptive cellular therapy, cytokine immunotherapy, cancer vaccines, and photoimmunotherapy have shown promising feasibility and efficacy in relevant preclinical and clinical studies. Future directions for OSCC immunotherapy include precision medicine and research into the pathogenesis of immune-related adverse events (irAEs) and standardization of management methods. Furthermore, nano-immunotherapy is expected to be a significant trend in OSCC treatment. Clinical trial number Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.